Literature DB >> 10976648

Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk.

F Licastro1, S Pedrini, C Ferri, V Casadei, M Govoni, A Pession, F L Sciacca, F Veglia, G Annoni, M Bonafè, F Olivieri, C Franceschi, L M Grimaldi.   

Abstract

Plasma levels of alpha1-antichymotrypsin (ACT) and interleukin-1beta (IL-1beta) were increased in patients with probable Alzheimer's disease (AD). A common polymorphism within ACT and IL-1beta genes affected plasma levels of ACT or IL-1beta, and AD patients with the ACT T,T or IL-1beta T,T genotype showed the highest levels of plasma ACT or IL-1beta, respectively. The concomitant presence of the ACT T,T and IL-1beta T,T genotypes increased the risk of AD (odds ratio: 5.606, confidence interval: 1.654-18.996) and decreased the age at onset of the disease.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10976648

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  23 in total

Review 1.  Local neuroinflammation and the progression of Alzheimer's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study.

Authors:  K S Benke; M C Carlson; B Q Doan; J D Walston; Q L Xue; A P Reiner; L P Fried; D E Arking; A Chakravarti; M D Fallin
Journal:  Exp Gerontol       Date:  2011-09-24       Impact factor: 4.032

3.  Polymorphisms for interleukin-1 beta (IL-1 beta)-511 promoter, IL-1 beta exon 5, and IL-1 receptor antagonist: nonassociation with endometriosis.

Authors:  Y Y Hsieh; C C Chang; F J Tsai; J Y Wu; Y R Shi; H D Tsai; C H Tsai
Journal:  J Assist Reprod Genet       Date:  2001-09       Impact factor: 3.412

4.  Chemotherapy-Induced Neurotoxicity: Evidence of a Protective Role of CC Homozygosis in the Interleukin-1β Gene-511 C>T Polymorphism.

Authors:  E Peila; F D'Agata; P Caroppo; L Orsi; P Mortara; S Cauda; M Manfredi; M M Caglio; P Fenoglio; B Baudino; G Castellano; G Bisi; L Pinessi; S Gallone
Journal:  Neurotox Res       Date:  2016-06-07       Impact factor: 3.911

5.  Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study.

Authors:  Matthew Zabel; Matthew Schrag; Claudius Mueller; Weidong Zhou; Andrew Crofton; Floyd Petersen; April Dickson; Wolff M Kirsch
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Authors:  J E Nelson; P Handa; B Aouizerat; L Wilson; L A Vemulakonda; M M Yeh; K V Kowdley
Journal:  Aliment Pharmacol Ther       Date:  2016-10-11       Impact factor: 8.171

7.  Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease.

Authors:  M Ilyas Kamboh; Ryan L Minster; Margaret Kenney; Ayla Ozturk; Purnima P Desai; Candace M Kammerer; Steven T DeKosky
Journal:  Neurobiol Aging       Date:  2005-08-30       Impact factor: 4.673

8.  Genetic polymorphism of interleukin 1β -511C/T and susceptibility to sporadic Alzheimer's disease: a meta-analysis.

Authors:  Hai Yuan; Qing Xia; Pingping Ge; Shaowei Wu
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

9.  Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Cheng-Sheng Chen; Chia-Hsiang Chen; Chia-Ju Hsieh; Yau-Yau Wai; Chee-Jen Chang; Hsiao-Jung Tseng; Tzue-Chen Yen; Chia-Yih Liu; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04       Impact factor: 9.236

10.  Genetic analysis of interleukin-1A C(-889)T polymorphism with Alzheimer disease.

Authors:  Ji-Liang Hu; Gang Li; De-Xiang Zhou; Yu-Xi Zou; Zhi-Shan Zhu; Ru-Xiang Xu; Xiao-Dan Jiang; Yan-Jun Zeng
Journal:  Cell Mol Neurobiol       Date:  2008-08-15       Impact factor: 5.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.